Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance - PubMed (original) (raw)

Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance

Chloe S Chaudhury et al. Clin Infect Dis. 2019.

Abstract

Background: Hepatitis C virus (HCV) and hepatic dysfunction are associated with low total and free testosterone (TT and FT) and high sex hormone-binding globulin (SHBG). However, little is known about changes in testosterone following successful HCV treatment.

Methods: We evaluated testosterone levels and the prevalence of low testosterone in a cohort of 327 men with chronic HCV infection (human immunodeficiency virus [HIV] coinfection = 150) and in a subset of 85 men with testosterone levels obtained pre-HCV treatment and after sustained virologic response (SVR). Median follow-up was 36 months.

Results: Participants with active HCV at baseline had higher TT (P < .0001) and SHBG (P < .0001) compared with participants who had achieved SVR, whereas FT did not differ. Low TT (<10.4 nmol/L) was more prevalent in participants with SVR compared with active HCV (P = .002); however, low FT (<0.1735 nmol/L) was common (50% active HCV, 43% SVR) and did not different between groups. For participants with longitudinal determinations, TT and SHBG decreased significantly (P < .0001) while FT remained unchanged post-SVR. Low FT persisted after SVR (pre-treatment 58%, post-SVR 54%, P = .72). HIV status and change in aspartate aminotrasferase-to-platelet ratio were significant independent predictors of change in FT following SVR.

Conclusions: During active HCV infection, testosterone deficiency may be masked due to elevated SHBG. Despite improvements in SHBG following SVR, low FT was common and persisted after HCV clearance, indicating the need for enhanced awareness and screening using estimates of FT following successful treatment of chronic HCV.

Clinical trials registration: NCT01350648.

Keywords: HCV; SHBG; SVR; hypogonadism; testosterone.

Published by Oxford University Press for the Infectious Diseases Society of America 2019.

PubMed Disclaimer

Comment in

References

    1. Kumar P, Kumar N, Thakur DS, Patidar A. Male hypogonadism: symptoms and treatment. J Adv Pharm Technol Res 2010; 1:297–301. - PMC - PubMed
    1. Sinclair M, Grossmann M, Gow PJ, Angus PW. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol 2015; 30:244–51. - PubMed
    1. Hofny ER, Ali ME, Taha EA, et al. Semen and hormonal parameters in men with chronic hepatitis C infection. Fertil Steril 2011; 95:2557–9. - PubMed
    1. Durazzo M, Premoli A, Di Bisceglie C, et al. Alterations of seminal and hormonal parameters: an extrahepatic manifestation of HCV infection?World J Gastroenterol 2006; 12:3073–6. - PMC - PubMed
    1. Nguyen HV, Mollison LC, Taylor TW, Chubb SA, Yeap BB. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-alpha therapy. Intern Med J 2006; 36:362–6. - PubMed

MeSH terms

Substances

LinkOut - more resources